ARQT Arcutis Biotherapeutics Inc
Price (delayed)
$14.98
Market cap
$1.78B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.16
Enterprise value
$1.82B
Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent
Highlights
Arcutis Biotherapeutics's equity has surged by 78% YoY
ARQT's EPS has soared by 69% YoY and by 30% QoQ
Arcutis Biotherapeutics's quick ratio has surged by 64% QoQ but it has decreased by 42% YoY
Key stats
What are the main financial stats of ARQT
Market
Valuations
Earnings
Shares outstanding
118.64M
Market cap
$1.78B
Enterprise value
$1.82B
Price to earnings (P/E)
N/A
Price to book (P/B)
11.13
Price to sales (P/S)
9.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.24
Revenue
$196.54M
Gross profit
$177.41M
Operating income
-$128.4M
Net income
-$140.04M
EBIT
-$112.22M
EBITDA
-$109.22M
Free cash flow
-$112.3M
Per share
Balance sheet
Liquidity
EPS
-$1.16
EPS diluted
-$1.16
Free cash flow per share
-$0.93
Book value per share
$1.35
Revenue per share
$1.62
TBVPS
$2.81
Total assets
$348.89M
Total liabilities
$191.35M
Debt
$110.59M
Equity
$157.54M
Working capital
$254.81M
Debt to equity
0.7
Current ratio
4.15
Quick ratio
3.72
Net debt/EBITDA
-0.35
Margins
Efficiency
Dividend
EBITDA margin
-55.6%
Gross margin
90.3%
Net margin
-71.3%
Operating margin
-65.3%
Return on assets
-32.8%
Return on equity
-77.2%
Return on invested capital
-28.5%
Return on capital employed
-41.9%
Return on sales
-57.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARQT stock price
How has the Arcutis Biotherapeutics stock price performed over time
Intraday
-4.22%
1 week
-12.45%
1 month
9.42%
1 year
54.75%
YTD
7.54%
QTD
-4.22%
Financial performance
How have Arcutis Biotherapeutics's revenue and profit performed over time
Revenue
$196.54M
Gross profit
$177.41M
Operating income
-$128.4M
Net income
-$140.04M
Gross margin
90.3%
Net margin
-71.3%
The operating margin has soared by 84% YoY and by 50% from the previous quarter
Arcutis Biotherapeutics's net margin has surged by 84% YoY and by 49% QoQ
Arcutis Biotherapeutics's net income has increased by 47% YoY and by 28% QoQ
The company's operating income rose by 47% YoY and by 29% QoQ
Growth
What is Arcutis Biotherapeutics's growth rate over time
Valuation
What is Arcutis Biotherapeutics stock price valuation
P/E
N/A
P/B
11.13
P/S
9.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.24
ARQT's EPS has soared by 69% YoY and by 30% QoQ
The stock's price to book (P/B) is 128% more than its 5-year quarterly average of 5.1 and 71% more than its last 4 quarters average of 6.8
Arcutis Biotherapeutics's equity has surged by 78% YoY
The company's revenue rose by 42% QoQ
The price to sales (P/S) is 7% higher than the last 4 quarters average of 9.0
Efficiency
How efficient is Arcutis Biotherapeutics business performance
ARQT's ROS has soared by 85% YoY and by 52% QoQ
The ROE has soared by 74% YoY and by 35% from the previous quarter
ARQT's return on assets has surged by 58% year-on-year and by 29% since the previous quarter
The company's return on invested capital has surged by 51% YoY and by 28% QoQ
Dividends
What is ARQT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARQT.
Financial health
How did Arcutis Biotherapeutics financials performed over time
ARQT's total assets is 82% greater than its total liabilities
The current ratio has soared by 69% from the previous quarter but it has contracted by 41% YoY
Arcutis Biotherapeutics's quick ratio has surged by 64% QoQ but it has decreased by 42% YoY
Arcutis Biotherapeutics's debt is 30% lower than its equity
Arcutis Biotherapeutics's equity has surged by 78% YoY
ARQT's debt to equity has dropped by 70% year-on-year and by 47% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.